All In Biotech

Drug Trial Radar · NCT03063762

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

An Open-Label, Multi-Center, Randomized, Dose-Escalation, Phase 1b Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 in Combination With Atezolizumab ± Bevacizumab in Patients With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Feb 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

69

Actual

Start

Mar 20, 2017

Primary completion

Jun 14, 2021

Study completion Jun 14, 2021

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, randomized, Phase 1b, adaptive, clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary therapeutic activity of RO6874281 in combination with atezolizumab with/without bevacizumab in participants with unresectable advanced and/or metastatic RCC. The study will consist of a dose-escalation part and an extension part.

Conditions

  • Renal Cell Carcinoma

Interventions

  • AtezolizumabDrug

    Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part. Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule

  • BevacizumabDrug

    Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards. In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle.

  • RO6874281Drug

    Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part. In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Arm A: It ends one week after the second administration of RO6874281 + atezolizumab Arm B: one week after the first administration of RO6874281 + atezolizumab + bevacizumab
  2. Maximum Tolerated Dose (MTD) of RO6874281Time frame: Arm A: It ends one week after the second administration of RO6874281 + atezolizumab Arm B: one week after the first administration of RO6874281 + atezolizumab + bevacizumab
  3. Recommended Dose of RO6874281Time frame: Arm A: It ends one week after the second administration of RO6874281 + atezolizumab Arm B: one week after the first administration of RO6874281 + atezolizumab + bevacizumab
  4. Percentage of Participants with Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: Screening until disease progression or study treatment discontinuation (assessed at every 8 weeks after study treatment start for the first year, and every 12 weeks thereafter, up to 24 months)

Locations

23 sites in 9 countries. Site status is shown where the registry gives one.

  • Yale Cancer Center; Medical Oncology

    New Haven, Connecticut

  • Northwestern Center for Clinical Research; Cancer Center

    Chicago, Illinois

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Herlev Hospital; Afdeling for Kræftbehandling

    Herlev, Denmark

  • Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes

    Lyon, France

  • Institut Claudius Regaud; Departement Oncologie Medicale

    Toulouse, France

  • Universitätsklinikum Tübingen; Klinik für Urologie

    Tübingen, Germany

  • Uniklinikum, Comprehensive Cancer Center Mainfranken; Interdisziplinäres Studienzentrum mit ECTU

    Würzburg, Germany

  • Universita di Modena e Reggio Emilia;Dipartimento di Oncologia ed Ematologia

    Modena, Emilia-Romagna, Italy

  • Fondazione IRCCS Policlinico San Matteo, Oncologia

    Pavia, Lombardy, Italy

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital del Mar; Servicio de Oncologia

    Barcelona, Spain

  • Hospital Univ Vall d'Hebron; Servicio de Oncologia

    Barcelona, Spain

  • Hospital Clínic i Provincial; Servicio de Oncología

    Barcelona, Spain

  • Hospital Ramon y Cajal; Servicio de Oncologia

    Madrid, Spain

  • START Madrid-FJD, Hospital Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia

    Valencia, Spain

  • Clinica Universitaria de Navarra; Servicio de Oncologia

    Pamplona, Navarre, Spain

  • Barts & London School of Med; Medical Oncology

    London, United Kingdom

  • The Christie

    Manchester, United Kingdom

  • Southampton General Hospital; Medical Oncology

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.